Furthermore, these studies employed a range of tumor-agnostic, single-nucleotide variant (SNV)-based ctDNA methodologies, including next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) of gene alterations of interest (e.g., PIK3CA, ESR1) with varying sensitivities that may depend on tumor genotypes7. This evidence concerns the gene PIK3CA and neoplasm.